131 related articles for article (PubMed ID: 37137831)
1. [Evaluation of clinical safety and diagnostic efficacy of domestic liver-specific magnetic resonance contrast agent (gadoxetate disodium)].
Yang T; Ye Z; Yao S; Li Y; Song B
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):161-167. PubMed ID: 37137831
[No Abstract] [Full Text] [Related]
2. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
[TBL] [Abstract][Full Text] [Related]
3. Transient Severe Motion Artifact Related to Gadoxetate Disodium-Enhanced Liver MRI: Frequency and Risk Evaluation at a German Institution.
Well L; Rausch VH; Adam G; Henes FO; Bannas P
Rofo; 2017 Jul; 189(7):651-660. PubMed ID: 28445909
[No Abstract] [Full Text] [Related]
4. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
5. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.
Jang HJ; Choi SH; Choi SJ; Choi WM; Byun JH; Won HJ; Shin YM
Eur Radiol; 2023 Aug; 33(8):5792-5800. PubMed ID: 37017700
[TBL] [Abstract][Full Text] [Related]
6. Respiratory motion artifact affecting hepatic arterial phase MR imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium.
Bashir MR; Castelli P; Davenport MS; Larson D; Marin D; Hussain HK; Jaffe TA
Radiology; 2015 Jan; 274(1):141-8. PubMed ID: 25162310
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
Kim YY; An C; Kim S; Kim MJ
Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
[TBL] [Abstract][Full Text] [Related]
8. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
[TBL] [Abstract][Full Text] [Related]
9. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR
J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
11. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR
J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120
[TBL] [Abstract][Full Text] [Related]
12. Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria.
Choi SH; Byun JH; Kim SY; Lee SJ; Won HJ; Shin YM; Kim PN
Invest Radiol; 2016 Aug; 51(8):483-90. PubMed ID: 26885632
[TBL] [Abstract][Full Text] [Related]
13. Comparison of transient severe motion in gadoxetate disodium and gadopentetate dimeglumine-enhanced MRI: effect of modified breath-holding method.
Song JS; Choi EJ; Park EH; Lee JH
Eur Radiol; 2018 Mar; 28(3):1132-1139. PubMed ID: 28986630
[TBL] [Abstract][Full Text] [Related]
14. Extended application of subtraction arterial phase imaging in LI-RADS version 2018: a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI.
Kim SS; Lee S; Bae H; Chung YE; Choi JY; Park MS; Kim MJ
Eur Radiol; 2021 Mar; 31(3):1620-1629. PubMed ID: 32886205
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
Allen BC; Ho LM; Jaffe TA; Miller CM; Mazurowski MA; Bashir MR
AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
[TBL] [Abstract][Full Text] [Related]
16. Profiling hepatocellular carcinoma aggressiveness with contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI: An intra-individual comparative study based on the Liver Imaging Reporting and Data System.
Yang J; Jiang H; Xie K; Bashir MR; Wan H; Huang J; Qin Y; Chen J; Lu Q; Song B
Eur J Radiol; 2022 Sep; 154():110397. PubMed ID: 35696735
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.
Rong D; He B; Tang W; Xie S; Kuang S; Grazioli L; Hussain SM; Yang Y; Wang J
AJR Am J Roentgenol; 2022 Apr; 218(4):687-698. PubMed ID: 34817191
[No Abstract] [Full Text] [Related]
18. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
Lee HS; Kim MJ; An C
Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
[TBL] [Abstract][Full Text] [Related]
19. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
Lee S; Kim SS; Chang DR; Kim H; Kim MJ
Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
[TBL] [Abstract][Full Text] [Related]
20. Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging.
Kang JH; Choi SH; Byun JH; Kim DH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
Eur Radiol; 2020 May; 30(5):2881-2889. PubMed ID: 32020399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
